A Dose-response Study of Dietary Resveratrol on Lipid Metabolism Disorder
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 168 participants.
Also called NCT04886297
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose prevention
- Phase
- Phase 3
- Enrolled
- 168 participants
- Sponsor
- Registry
-
NCT04886297
-
- Other papers using this trial's data
- A Randomized Trial on Resveratrol Supplement Affecting Lipid Profile and Other Metabolic Markers in Subjects with Dyslipidemia
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT04886297. Randomized; double masking; primary purpose prevention. Start 2021-05-01 (actual); primary completion 2022-05-30 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Dose-response Study of Dietary Resveratrol on Lipid Metabolism Disorder
- Condition
- Dyslipidemias
- Intervention (Drug)
- Mega Resveratrol® capsules
- Intervention (Drug)
- Mega Resveratrol® Placebo capsules
- Lead sponsor
- Sun Yat-sen University
Record details
- Record id
cardio:ct-nct04886297- Content hash
9a8f1777522a97cc580829575e10f119cdfcd1f859d82ba1e6995a8669262200